![Nadim Ahmed](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nadim Ahmed
Vorstandsvorsitzender bei
CULLINAN THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 31.07.2026
Profil
Mr. Nadim Ahmed is a President, Chief Executive Officer & Director at Cullinan Therapeutics, Inc., a President, Chief Executive Officer & Director at Cullinan Mica Corp.
and a President, Chief Executive Officer & Director at Cullinan Pearl Corp.
He is on the Board of Directors at Disc Medicine, Inc., Cullinan Therapeutics, Inc., Family Promise, Cullinan Mica Corp.
and Cullinan Pearl Corp.
Mr. Ahmed was previously employed as a President, Chief Executive Officer & Director by Cullinan Oncology LLC, a President-Hematology by Bristol Myers Squibb Co., a President-Global Hematology & Oncology by Celgene Corp., and a Senior Marketing Director-Hematologic Oncology by GlaxoSmithKline LLC.
He received his undergraduate degree from the University College London and a graduate degree from Loughborough University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 01.04.2026 | 135’921 ( 0.23% ) | 2 Mio $ | 31.07.2026 |
Aktive Positionen von Nadim Ahmed
| Unternehmen | Position | Beginn |
|---|---|---|
| CULLINAN THERAPEUTICS, INC. | Vorstandsvorsitzender | 18.10.2021 |
| DISC MEDICINE, INC. | Direktor/Vorstandsmitglied | 14.07.2025 |
Family Promise
 Family Promise Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization to help homeless and low-income families | Direktor/Vorstandsmitglied | - |
Cullinan Pearl Corp.
 Cullinan Pearl Corp. BiotechnologyHealth Technology Develops an orally available tyrosine kinase inhibitor | Vorstandsvorsitzender | - |
Cullinan Mica Corp.
 Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Nadim Ahmed
| Unternehmen | Position | Ende |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.01.2021 |
| CELGENE | Corporate Officer/Principal | 01.11.2019 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Corporate Officer/Principal | 01.03.2010 |
Cullinan Oncology LLC
 Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Vorstandsvorsitzender | - |
Ausbildung von Nadim Ahmed
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
80
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
University College London
 University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Loughborough University
 Loughborough University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Family Promise
Family Promise Miscellaneous Commercial ServicesCommercial Services Operates as non-profit organization to help homeless and low-income families | Commercial Services |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Cullinan Mica Corp.
Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Develops immuno-oncology therapeutics | Health Technology |
Cullinan Oncology LLC
Cullinan Oncology LLC Financial ConglomeratesFinance Provides investment services for cancer treatments | Finance |
Cullinan Pearl Corp.
Cullinan Pearl Corp. BiotechnologyHealth Technology Develops an orally available tyrosine kinase inhibitor | Health Technology |
Cullinan Oncology, Inc.
 Cullinan Oncology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Disc Medicine, Inc.
 Disc Medicine, Inc. BiotechnologyHealth Technology Develops therapies addressing red blood cell production in hematologic diseases | Health Technology |
